(Q43668317)

25 November 2017

title

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer (English)

1 reference

25 November 2017

main subject

phase I clinical trial

0 references

1 reference

N Haas

1

1 reference

25 November 2017

B Roth

2

1 reference

25 November 2017

C Garay

3

1 reference

25 November 2017

G Yeslow

4

1 reference

25 November 2017

M Entmacher

5

1 reference

25 November 2017

A Weinstein

6

1 reference

25 November 2017

A Rogatko

7

1 reference

25 November 2017

J Babb

8

1 reference

25 November 2017

C Minnitti

9

1 reference

25 November 2017

D Flinker

10

1 reference

25 November 2017

T Gillon

11

1 reference

25 November 2017

G Hudes

12

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

58

1 reference

25 November 2017

issue

1

1 reference

25 November 2017

page(s)

59-64

1 reference

Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

The chemotherapy of prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Paclitaxel-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Cancer phase I clinical trials: efficient dose escalation with overdose control.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase I trial of weekly paclitaxel in advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Thromboembolic events with paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

Thromboembolic events with paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901011-1

7 January 2021

10.1016/S0090-4295(01)01011-1

Identifiers

DOI

1 reference

25 November 2017

1 reference